Barry Burgdorf

Partner

Hogan Lovells

Office Phone:

CONFIDENTIAL

Direct Phone:

CONFIDENTIAL

Email:

confidential@email.com


Try Free
 

    and access,

  •     83K PE/M&A Contacts
  •     +
  •     4.8K PE Firms
  •     3.8K M&A Advisors
  •     214K Transactions
  •     216K Companies

  •     Market Services
  •     Build Lists
  •     Research Sectors
  •     Uncover Opportunities

Barry Burgdorf Bio

Barry Burgdorf helps public and private companies, emerging companies, and venture capital, private equity, and higher education clients, with a variety of complex mergers, acquisitions, financings, IP intensive, corporate transactions in the life sciences and other technology industries (software, AI / semiconductor, energy transition), and higher education (commercialization, research and development, compliance). He has served as general counsel, outside counsel, and as part of the corporate suite at a life sciences company offering AI powered diagnostic tools for radiologists and at a biotech venture capital fund, providing him with a holistic view and an inside track on business-critical needs. Barry regularly advises clients in the higher education and life sciences space, representing both universities and corporations of all sizes around the globe. Following his time as a business litigator, Barry was a corporate securities and M&A partner at another global law firm. Barry also previously served as Vice Chancellor and General Counsel of the University of Texas System, where, for over eight years, he served as a key member of the leadership team and oversaw legal, real estate, cybersecurity, IT, and technology transfer matters. As Vice Chancellor and GC of UT System, Barry negotiated with several U.S. government agencies, including The Department of Education, The Department of Energy, The Department of Homeland Security, and The National Institutes of Health, among others. He was also the first General Counsel of Samsung Austin Semiconductors, where he worked on construction of Samsung's DRAM fabrication plant and several large equity and equipment financings. He is on the Board of several life sciences and health care companies including an AI driven mobile app for advanced pathogen surveillance.